SUSQUEHANNA INTERNATIONAL GROUP, LLP - ENANTA PHARMACEUTICALS INC ownership

ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 156 filers reported holding ENANTA PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.10 and the average weighting 0.2%.

Quarter-by-quarter ownership
SUSQUEHANNA INTERNATIONAL GROUP, LLP ownership history of ENANTA PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$989,159
+271.9%
88,555
+612.5%
0.00%
Q2 2023$265,959
-92.9%
12,428
-86.5%
0.00%
Q1 2023$3,736,090
+8.4%
92,386
+24.7%
0.00%
-100.0%
Q4 2022$3,446,806
-33.9%
74,093
-26.4%
0.00%0.0%
Q3 2022$5,218,000
+93.3%
100,608
+76.2%
0.00%
Q2 2022$2,699,000
-10.7%
57,093
+34.5%
0.00%
Q1 2022$3,021,000
-61.3%
42,437
-59.4%
0.00%
Q4 2021$7,816,000
+348.2%
104,532
+240.6%
0.00%
Q3 2021$1,744,000
+16.7%
30,693
-9.6%
0.00%
Q2 2021$1,495,000
-57.2%
33,952
-52.0%
0.00%
Q1 2021$3,492,000
-41.3%
70,802
-49.9%
0.00%
Q4 2020$5,948,000
+983.4%
141,270
+1077.2%
0.00%
Q3 2020$549,000
+54.2%
12,000
+69.1%
0.00%
Q2 2020$356,000
-72.4%
7,097
-71.7%
0.00%
Q1 2020$1,288,000
-74.1%
25,039
-68.9%
0.00%
-100.0%
Q4 2019$4,980,000
-46.4%
80,600
-47.9%
0.00%
-33.3%
Q3 2019$9,296,000
-80.0%
154,737
-71.9%
0.00%
-50.0%
Q2 2019$46,511,000
+870.0%
551,214
+998.0%
0.01%
+200.0%
Q1 2019$4,795,000
-19.4%
50,200
-40.2%
0.00%0.0%
Q4 2018$5,950,000
+31.1%
84,000
+58.2%
0.00%
+100.0%
Q3 2018$4,538,000
-37.6%
53,100
-15.4%
0.00%
-66.7%
Q2 2018$7,277,000
+129.8%
62,793
+60.4%
0.00%
+200.0%
Q1 2018$3,166,000
+433.9%
39,136
+287.5%
0.00%
Q4 2017$593,000
-55.2%
10,100
-64.3%
0.00%
Q3 2017$1,325,000
-68.7%
28,300
-76.0%
0.00%
-100.0%
Q2 2017$4,239,000
+155.8%
117,815
+119.0%
0.00%0.0%
Q1 2017$1,657,000
+240.9%
53,800
+271.0%
0.00%
Q4 2016$486,000
-37.2%
14,500
-50.2%
0.00%
Q3 2016$774,000
-38.9%
29,100
-49.3%
0.00%
Q2 2016$1,266,000
-70.2%
57,400
-60.3%
0.00%
-100.0%
Q1 2016$4,243,000
-38.5%
144,495
-30.9%
0.00%
+50.0%
Q4 2015$6,900,000
+162.9%
208,969
+187.7%
0.00%
+100.0%
Q3 2015$2,625,000
-22.5%
72,640
-3.5%
0.00%
-50.0%
Q2 2015$3,389,000
+35.8%
75,306
-7.6%
0.00%
+100.0%
Q1 2015$2,496,000
-65.6%
81,518
-42.8%
0.00%
-50.0%
Q4 2014$7,248,000
+126.7%
142,527
+76.4%
0.00%
+100.0%
Q3 2014$3,197,000
+30.6%
80,781
+42.2%
0.00%
Q2 2014$2,447,000
+1043.5%
56,804
+961.4%
0.00%
Q1 2014$214,0005,3520.00%
Other shareholders
ENANTA PHARMACEUTICALS INC shareholders Q2 2022
NameSharesValueWeighting ↓
Krensavage Asset Management, LLC 858,811$36,156,00010.56%
Fairmount Funds Management LLC 150,433$6,333,0002.26%
ARMISTICE CAPITAL, LLC 1,356,000$57,088,0001.94%
FARALLON CAPITAL MANAGEMENT LLC 1,775,000$74,728,0000.45%
Virtus ETF Advisers LLC 14,321$603,0000.25%
Granahan Investment Management 231,071$9,728,0000.22%
JACOBS LEVY EQUITY MANAGEMENT, INC 248,320$10,454,0000.09%
ACADIAN ASSET MANAGEMENT LLC 467,514$19,684,0000.08%
VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. 126$5,0000.08%
AIGEN INVESTMENT MANAGEMENT, LP 12,854$541,0000.07%
View complete list of ENANTA PHARMACEUTICALS INC shareholders